January 16, 2020 6:09pm

The Advance/Decline (A/D) line is slipping while 5 out of the 18 upside had higher than the 3 month average volume and 9 out of the 15 downside had higher than the 3 month average volume

Pre-open indications: I abstained due to family emergency

It's a daunting task to understand risk, seeing the unforeseen; on the basis of my own “rules”, I set-up my own “warning analysis” which isn’t machine oriented!

 

The Dow closed UP +242.61 points (+0.84%), the S&P closed UP +27.52 points (+0.84%) and the NASDAQ closed UP +98.44 points (+1.06%)

 

Henry’omics:

Indexes rose on Thursday to fresh record highs after Morgan Stanley reported quarterly figures that easily topped analyst expectations while investors digested solid data on the U.S. economy.

Strong economic data lifted sentiment. Weekly jobless claims unexpectedly dropped by 10,000 to 204,000. Economists expected a print of 216,000; retail sales climbed by 0.3% in December matching expectation. The Philadelphia Fed business index also jumped to 17 in January from 2.4 in December.

 

As far as “our’ universe of cell and gene therapy sector is concerned – we NEED a better messaging  of differentiation of platforms and comparables  as well as relative of these possible medications and treatments.

Exits will also be a tool of selling the investment paradigm.

Executive salaries also need to be measured by advancement of platforms and R&D expenses need to be plotted against G&A expense versus time in development!

Pay for performance with bonuses, forget the options – they are becoming irrelevant!

Options and warrants are similar – open a draw and stick them in the old paint shirt section – I don’t paint anymore!

 

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Thursday the IBB closed up +0.62% while and XBI closed up +0.73%
  • Wednesday the IBB closed up +0.62% while and XBI closed up +0.73%
  • Tuesday the IBB closed up +1.95% while and XBI closed up +2.73%
  • Monday the IBB closed down -1.209% while and XBI closed down -1.91%

 

The advance/decline line scenario of 35 covered companies:

  • Thursday the close was positive with an A/D line of 18/15, 2 flats of 35 covered,
  • Wednesday the close was positive with an A/D line of 20/14, 1 flat of 35 covered,
  • Tuesday the close was positive with an A/D line of 28/7, 1 flat of 35 covered,
  • Monday the close was negative with an A/D line of 10/24, 1 flat of 35 covered,

 

Decliners:

  • uniQure (QURE -$2.91);
  • Sage Therapeutics (SAGE -$0.82 after Wednesday’s +$1.68);
  • Editas Medicine (EDIT -$0.76 after Wednesday’s +$0.35);
  • Ionis Pharmaceuticals (IONS -$0.60 after Wednesday’s -$1.22);
  • Intrexon (XON -$0.59);

Incliners:

  • bluebird bio (BLUE +$3.55 after Wednesday’s +$1.66 and Tuesday’s +$5.45);
  • Global Blood Therapeutics (GBT +$1.52 after Wednesday’s +$1.65, Tuesday’s +$3.08 and  Monday’s-$2.17);
  • Regenxbio (RGNX +$1.49 after Wednesday’s +$0.81 and Tuesday’s +$2.87);
  • Alnylam Pharmaceuticals (ALNY +$1.25 after Wednesday’s -$0.43, Tuesday’s+$3.79 and Monday’s -$4.60);
  • Vericel (VCEL +$0.43 after Wednesday’s +$0.48);

 

The percentage (%) indicators:

  • Thursday’s range of the 18 upside was +0.12% (CRSP) to +25.52% (BLCM) while the 15 downside ranged from -0.48% (MESO) to -8.68% (XON); 
  • Wednesday’s range of the 20 upside was +0.23% (BCLI) to +4.92% (VSTM) while the 14 downside ranged from -0.19% (QURE) to -5.56% (XON); 
  • Tuesday’s range of the 28 upside was +0.02% (IONS) to +17.45% (BLCM) while the 7 downside ranged from -0.50% (MESO) to -33.30% (STML); 
  • Monday’s range of the 10 upside was +0.50% (BOLD) to +6.60% (RARE) while the 25 downside ranged from -078% (SGMO) to -11.07% (AXGN); 

 

Upside volume stats:  to compare

  • Thursday: 5 out of the 18 upside had higher than the 3 month average volume;
  • Wednesday: 6 out of the 20 upside had higher than the 3 month average volume;
  • Tuesday: 19 out of the 28 upside had higher than the 3 month average volume;
  • Monday: 6 out of the 10 upside had higher than the 3 month average volume;

 

Downside volume stats:

  • Thursday: 9 out of the 15 downside had higher than the 3 month average volume;
  • Wednesday: 4 out of the 14 downside had higher than the 3 month average volume;
  • Tuesday: 4 out of the 7 downside had higher than the 3 month average volume;
  • Monday: 11 out of the 25 downside had higher than the 3 month average volume;

2 flat – BLFS & RENE.L

 

January’s sessions of 35 covered companies:

Thursday closed POSITIVE with 15 decliners, 18 advancers and 2 flat3;

Wednesday closed POSITIVE with 14 decliners, 20 advancers and 1 flat;

Tuesday closed POSITIVE with 7 decliners, 28 advancers and 1 flat;

Monday closed NEGATIVE with 24 decliners, 10 advancers and 1 flat;

Friday closed NEGATIVE with 18 decliners, 16 advancers and 1 flat;

Thursday closed POSITIVE with 12 decliners, 22 advancers and 1 flat;

Wednesday closed POSITIVE with 10 decliners, 23 advancers and 2 flats;

Tuesday closed POSITIVE with 15 decliners, 22 advancers and 0 flat;

Monday closed POSITIVE with 13 decliners, 22 advancers and 0 flat;

Friday closed NEGATIVE with 19 decliners, 15 advancers and 1 flat;

Thursday closed NEGATIVE with 18 decliners, 15 advancers and 2 flats;

Wednesday markets were closed;

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.